Description: Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Home Page: www.enlivex.com
14 Einstein Street
Ness Ziona,
7403618
Israel
Phone:
972 2 670 8072
Officers
| Name | Title |
|---|---|
| Mr. Shai Novik M.B.A. | Executive Chairman |
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
| Ms. Shachar Shlosberger CPA | Chief Financial Officer |
| Mr. Veronique Amor-Baroukh | Senior Director of Operations |
| Ms. Sigal Arad | Director of HR |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9893 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |